Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT02825563
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Anlotinib in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02809534
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of AL2846 on Tolerance and Pharmacokinetics
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02779699
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02752516
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury
- Conditions
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT02734966
- Locations
- 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Nanjing Pulmonary Hospital, Nanjing, Jiangsu, China
A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT02671942
- Locations
- 🇨🇳
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT02649361
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT02622932
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 113
- Registration Number
- NCT02586337
- Locations
- 🇨🇳
Jiangsu province tumor hospital, Nanjing, Jiangsu, China
🇨🇳Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT02586350
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Harbin medical university affiliated tumor hospital, Harbin, Heilongjiang, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China